These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34200586)

  • 1. Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51.
    Yadav R; Zhai L; Kunda NK; Muttil P; Tumban E
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34200586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
    Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
    Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
    Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
    Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
    Tumban E; Peabody J; Peabody DS; Chackerian B
    PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
    Yadav R; Zhai L; Tumban E
    Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
    Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS
    J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus.
    Tumban E; Peabody J; Tyler M; Peabody DS; Chackerian B
    PLoS One; 2012; 7(11):e49751. PubMed ID: 23185426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
    Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
    Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
    Schellenbacher C; Kwak K; Fink D; Shafti-Keramat S; Huber B; Jindra C; Faust H; Dillner J; Roden RBS; Kirnbauer R
    J Invest Dermatol; 2013 Dec; 133(12):2706-2713. PubMed ID: 23752042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature.
    Peabody J; Muttil P; Chackerian B; Tumban E
    Papillomavirus Res; 2017 Jun; 3():116-120. PubMed ID: 28720444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT; Castellsagué X; Garland SM
    Vaccine; 2012 Nov; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL; Joura EA
    Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus.
    Saboo S; Tumban E; Peabody J; Wafula D; Peabody DS; Chackerian B; Muttil P
    Mol Pharm; 2016 May; 13(5):1646-55. PubMed ID: 27019231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses.
    Hunter Z; Tumban E; Dziduszko A; Chackerian B
    Vaccine; 2011 Jun; 29(28):4584-92. PubMed ID: 21549786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.